Severe Combined Immunodeficiency

Severe Combined Immunodeficiency Market Outlook

The global severe combined immunodeficiency (SCID) market is projected to reach approximately USD 6.5 billion by 2035, growing at a compound annual growth rate (CAGR) of 8.5% during the forecast period from 2025 to 2035. Key growth factors contributing to this upward trend include increasing awareness about SCID among healthcare professionals and the general public, advancements in treatment modalities, and the rising incidence of genetic disorders resulting in SCID. Moreover, the expanding pipeline of gene therapies and improved diagnostic techniques are expected to drive market growth significantly. The rise in healthcare expenditure, coupled with growing governmental and non-governmental support for rare diseases, further enhances the potential market growth. As more clinical studies are initiated and completed, the availability of new and effective treatment options will likely improve patient outcomes and expand market opportunities.

Growth Factor of the Market

The growth of the severe combined immunodeficiency market is primarily fueled by several interconnected factors that collectively enhance the landscape of treatment options available for patients. Firstly, the increasing prevalence of genetic disorders and immunodeficiencies has amplified the urgency for effective and innovative treatment methods. Advances in gene therapy and stem cell transplantation techniques have shown promising results, leading to a growing acceptance of these therapies within the medical community. Furthermore, the integration of advanced diagnostic tools allows for earlier detection and intervention, thereby improving patient prognosis significantly. Additionally, increased collaborations among pharmaceutical companies, research organizations, and healthcare institutions drive the development of novel therapies tailored specifically for SCID patients. Finally, public awareness campaigns and advocacy for rare diseases have bolstered funding and support for research initiatives, further enhancing the market's growth trajectory.

Key Highlights of the Market

• The global SCID market is expected to grow at a CAGR of 8.5% from 2025 to 2035.
• Gene therapy accounts for the largest market share due to its effectiveness in treating genetic disorders.
• North America is the leading region in market revenue, driven by advanced healthcare infrastructure.
• Increased awareness and early diagnostic measures are crucial for improving patient outcomes.
• Collaborations and partnerships are on the rise, facilitating the development of innovative therapies.

By Product Type

Gene Therapy:

Gene therapy represents a groundbreaking segment in the SCID market, particularly due to its ability to address the underlying genetic deficiencies that cause the disorder. This innovative treatment modality employs techniques to modify a patient's genes, enabling the production of functional proteins that are absent or defective in individuals with SCID. Notable advancements in gene therapy have showcased remarkable success in clinical trials, with some therapies receiving regulatory approvals, leading to an uptick in market demand. Not only does gene therapy offer the potential for a long-term cure, but it also significantly reduces the recurrence of severe infections associated with SCID. As research continues to evolve, more gene therapy options are expected to enter the market, further propelling growth in this segment.

Enzyme Replacement Therapy:

Enzyme replacement therapy (ERT) also plays a vital role in the treatment of SCID, particularly for specific deficiencies such as adenosine deaminase deficiency (ADA). ERT involves administering synthetic or recombinant enzymes to compensate for the lack of enzyme activity in patients. This therapy has demonstrated efficacy in alleviating symptoms and improving quality of life for individuals affected by certain types of SCID. As research progresses, new formulations and delivery methods are expected to enhance the effectiveness of ERT, thereby contributing to market growth. The increasing awareness of ADA deficiency and the need for ongoing treatment options will likely further solidify the position of enzyme replacement therapy within the overall SCID market.

Stem Cell Transplantation:

Stem cell transplantation is a cornerstone of treatment for severe combined immunodeficiency, especially for those who do not respond to other therapies. This procedure involves replacing the defective immune system with healthy stem cells from a suitable donor, allowing for the restoration of immune function. Over the years, advancements in transplantation techniques, donor matching processes, and post-transplant care have improved the success rates associated with this intervention. As the understanding of immunological compatibility improves, the number of successful transplants is expected to rise, directly impacting the market positively. Furthermore, the availability of cord blood and bone marrow stem cells has expanded treatment options for patients, making stem cell transplantation a significant contributor to the SCID market's growth.

Immunoglobulin Therapy:

Immunoglobulin therapy provides an alternative approach to managing SCID by delivering antibodies to patients, thereby enhancing their immune defenses against infections. This treatment is especially valuable for patients who may not be eligible for gene therapy or stem cell transplantation. Immunoglobulin therapy can be administered via intravenous or subcutaneous routes, offering flexibility and convenience for patients and healthcare providers. As the efficacy of this therapy continues to be validated through clinical research, its adoption is expected to grow, supporting overall market expansion. Moreover, the ongoing development of new formulations and delivery mechanisms aims to improve the patient's experience and therapeutic outcomes in the SCID population.

Others:

In addition to the aforementioned therapies, there are other treatment approaches available for severe combined immunodeficiency that cater to specific patient needs. These may include supportive care measures such as prophylactic antibiotics, antiviral medications, and nutritional support to help manage complications associated with SCID. This "other" category also encompasses emerging therapies that are still under investigation, which may offer additional treatment options in the future. As the research landscape continues to evolve, it is likely that novel therapies will emerge, further diversifying the treatment modalities available for SCID patients and contributing to the market's overall growth.

By Application

Pediatrics:

Pediatrics is the primary application segment for the severe combined immunodeficiency market, as SCID predominantly manifests in infants and young children. Early diagnosis is crucial in this demographic since the condition leaves patients extremely vulnerable to infections. The growing focus on newborn screening programs helps identify SCID early, leading to timely interventions and improved outcomes. Pediatric patients often require specialized care that takes into account their unique physiological and developmental needs, making targeted therapies essential. As a result, the demand for pediatric-specific treatments and management strategies continues to rise, driving growth in this segment of the SCID market.

Adults:

While SCID is primarily diagnosed in childhood, there is an emerging recognition of its manifestation in adults, particularly those who may have been misdiagnosed or undiagnosed in their youth. This segment represents a smaller but significant portion of the market, as adult patients require tailored treatment plans to address their unique health challenges. The increase in awareness regarding SCID among healthcare providers and patients alike has led to a gradual uptick in the diagnosis of adult cases, ultimately contributing to market growth. Ongoing research into the long-term effects of SCID and its treatment in adults further emphasizes the need for targeted therapies and management strategies for this population.

By Distribution Channel

Hospitals:

Hospitals play a crucial role in the distribution of SCID treatment options, serving as primary healthcare institutions that provide both diagnosis and treatment. Due to the complexity of SCID and associated conditions, hospitals are equipped with advanced medical infrastructure and specialized healthcare providers capable of delivering comprehensive care. This segment accounts for a significant share of the overall distribution channels, as patients often require multidisciplinary approaches involving various specialties, including immunology, hematology, and infectious diseases. The ongoing evolution of healthcare policies and reimbursement frameworks further solidifies the hospital's position as a key player in the distribution of SCID therapies.

Specialty Clinics:

Specialty clinics are becoming increasingly prominent in the SCID market, providing targeted care for patients with complex immune disorders. These clinics focus on specific therapeutic areas and often house experts specializing in immunology, enabling a more personalized approach to treatment. Their ability to offer specialized therapies, including gene and enzyme replacement therapies, contributes to their growing importance in the distribution landscape. As patients seek high-quality care tailored to their unique medical needs, specialty clinics are well-positioned to meet this demand, driving growth in this segment of the market.

Retail Pharmacies:

Retail pharmacies serve as accessible points of distribution for patients receiving ongoing treatment for SCID. These pharmacies provide essential medications, including immunoglobulin therapies and supportive care products, which are critical for managing the condition. The convenience of retail pharmacies is especially important for patients requiring regular medication refills, as they can offer localized services that improve patient compliance. With ongoing trends in the pharmacy sector, including the expansion of services such as immunizations and health screenings, retail pharmacies are increasingly becoming integral components of the overall healthcare ecosystem for SCID patients.

Online Pharmacies:

The rise of online pharmacies has transformed the way patients access medications for managing severe combined immunodeficiency. These digital platforms provide convenience and accessibility, allowing patients to order medications from the comfort of their homes. Online pharmacies often offer competitive pricing and home delivery services that cater to the needs of patients who may have mobility challenges or prefer discreet purchasing options. The increased adoption of telehealth services and online consultations further supports the growth of online pharmacies as an important distribution channel for SCID therapies, providing patients with a holistic and patient-centric approach to healthcare.

By Ingredient Type

Adenosine Deaminase Deficiency:

Adenosine deaminase deficiency (ADA) is one of the most common forms of severe combined immunodeficiency and represents a critical ingredient type in the treatment landscape. Patients with ADA experience a build-up of toxic metabolites that can severely compromise immune function. Innovative therapies, including enzyme replacement therapy and gene therapy, have shown promising outcomes in correcting this deficiency. The growing recognition of ADA deficiency in newborn screening programs has led to increased early diagnosis and intervention, thus driving the demand for targeted therapies. As research continues to evolve, additional treatment options for ADA deficiency are anticipated to emerge, further enhancing the market segment.

IL-2 Receptor Gamma Chain Deficiency:

IL-2 receptor gamma chain deficiency is another critical etiology of severe combined immunodeficiency and plays a significant role in the market's ingredient type segment. This genetic disorder affects the immune system's ability to respond to infections and can lead to life-threatening complications. Current treatment options primarily include stem cell transplantation, which has been effective in restoring immune function in affected patients. Ongoing research is focused on developing gene therapies that target the underlying genetic defect, thereby providing a more definitive treatment option. As awareness grows regarding IL-2 receptor gamma chain deficiency and its impact on SCID, the demand for specialized therapies in this segment is expected to rise.

Janus Kinase 3 Deficiency:

Janus kinase 3 deficiency is another important ingredient type in the severe combined immunodeficiency market, characterized by a significant impairment of immune cell signaling pathways. This deficiency presents unique treatment challenges, as affected patients may require individualized management strategies to address their specific immune deficiencies. Current treatment approaches largely involve stem cell transplantation and supportive care, aimed at managing recurrent infections. Advances in research are anticipated to yield new therapies that target the underlying mechanisms of Janus kinase 3 deficiency, ultimately expanding treatment options and driving growth in this segment of the market.

RAG1 or RAG2 Deficiency:

RAG1 and RAG2 deficiencies are critical genetic disorders that contribute to severe combined immunodeficiency, underlining the importance of this ingredient segment. Patients with these deficiencies experience a profound inability to produce functional T and B lymphocytes, resulting in severe immunocompromise. Stem cell transplantation remains the primary treatment modality, providing a potential long-term solution by restoring normal immune function. As research progresses, there is hope for the development of innovative therapeutic approaches targeting RAG deficiencies, which could further enhance treatment options available to patients and ultimately strengthen this segment of the SCID market.

Others:

Beyond the primary ingredient types, the "others" category encompasses various rare deficiencies and emerging treatments that may not fit neatly into existing classifications. This segment includes patients with less common genetic mutations that lead to severe combined immunodeficiency. The ongoing advancements in genetic research and understanding of immune system functioning are likely to shed light on these rarer conditions, potentially leading to new therapies tailored to address unique immunological needs. As the landscape of SCID continues to evolve, the "others" category may represent a significant growth opportunity, driven by increased research funding and a heightened focus on personalized medicine solutions for affected patients.

By Region

The severe combined immunodeficiency market is witnessing varied dynamics across different regions, influenced by factors such as healthcare infrastructure, research advancements, and patient demographics. North America currently dominates the global market, accounting for approximately 45% of the total revenue share. This is primarily attributed to the advanced healthcare systems, robust research funding, and the presence of key pharmaceutical players in the region. The North American market is projected to grow at a CAGR of 9.2%, driven by increasing awareness of SCID and the introduction of novel therapies. Furthermore, the establishment of comprehensive screening programs and advancements in gene therapy are expected to enhance patient outcomes, thereby bolstering market growth.

In contrast, the Europe region holds a significant share of the SCID market, accounting for roughly 30% of the total market revenue. The European market benefits from strong regulatory frameworks, extensive clinical research initiatives, and collaborative efforts among healthcare providers and pharmaceutical companies. Countries such as Germany, the UK, and France are leading the charge in SCID treatment advancements, focusing on innovative therapies and improved patient care. The Asia Pacific region, while currently representing a smaller share of the market at around 15%, is expected to witness the fastest growth rate, with a CAGR of 10.0% during the forecast period. This growth is attributed to increasing healthcare investments, rising awareness of rare diseases, and an expanding patient population, presenting significant opportunities for market players in this burgeoning region.

Opportunities

The severe combined immunodeficiency market is ripe with opportunities as advancements in medical technology and increased funding for research create a conducive environment for innovation. One prominent opportunity lies in the development of novel gene therapies, which have the potential to revolutionize the treatment landscape for SCID. As more research institutions and pharmaceutical companies invest in this area, the likelihood of discovering more effective therapies that target the underlying genetic causes of SCID increases. Furthermore, the growing trend towards personalized medicine presents an opportunity for tailored treatment plans that consider individual patient needs and genetic profiles, enhancing therapeutic efficacy and patient satisfaction. As awareness and understanding of SCID continue to grow, there is also potential for increased collaboration between stakeholders, including healthcare providers, researchers, and advocacy groups, fostering a unified approach to tackling this rare disorder.

Another substantial opportunity lies in the expansion of newborn screening programs aimed at early detection of SCID. As more countries implement comprehensive screening policies, the prompt identification of affected infants allows for timely interventions and better health outcomes. This proactive approach not only improves individual patient prognosis but also raises awareness about SCID among healthcare providers and the general public, potentially increasing the demand for treatment options. Additionally, as the global pharmaceutical landscape continues to evolve, there are opportunities for emerging market players to establish a presence in underserved regions, addressing the unmet needs of SCID patients worldwide. By leveraging technological innovations and forging strategic partnerships, these companies can contribute to the overall growth and accessibility of SCID therapies in the years to come.

Threats

Despite the promising growth prospects within the severe combined immunodeficiency market, certain threats could hinder its development. One significant threat is the increasing competition among pharmaceutical companies developing therapies for SCID and other rare diseases. As more players enter the market, there may be pricing pressures that drive down profit margins, posing challenges for smaller companies and startups attempting to carve out their niche. Furthermore, the rapid pace of technological advancements in the healthcare sector can create an environment of constant change, requiring companies to remain agile and innovative to keep up with emerging trends and therapies. If companies fail to adapt, they may struggle to maintain their competitive edge, potentially impacting their market share and profitability.

Another threat lies in the regulatory landscape, as stringent approval processes for new therapies can delay the introduction of innovative treatment options. Compliance with varying regulations across different regions may also pose challenges for companies seeking to expand their products globally. Moreover, any adverse effects associated with newly developed therapies can lead to increased scrutiny from regulatory bodies, affecting market confidence and patient acceptance of these treatments. Addressing these regulatory challenges and ensuring that products meet safety and efficacy standards will be critical for companies operating in the SCID market in order to navigate potential hurdles and succeed in the long term.

Competitor Outlook

• Novartis AG
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Amgen Inc.
• Bluebird Bio, Inc.
• Sanofi S.A.
• AbbVie Inc.
• Orgenesis Inc.
• Spark Therapeutics, Inc.
• Janssen Pharmaceuticals, Inc.
• Regeneron Pharmaceuticals, Inc.
• Genzyme Corporation
• Takeda Pharmaceutical Company Limited
• Merck & Co., Inc.
• BioMarin Pharmaceutical Inc.

The competitive landscape of the severe combined immunodeficiency market is characterized by a variety of players ranging from large pharmaceutical corporations to specialized biotechnology firms. Major companies such as Novartis AG and Gilead Sciences, Inc. dominate the market due to their extensive portfolios of innovative therapies and robust research and development capabilities. These companies are continually striving to enhance their therapeutic offerings through strategic partnerships, mergers, and acquisitions, ultimately aiming to expand their reach within the SCID market. Additionally, the increasing investment in research initiatives dedicated to rare genetic disorders has resulted in a growing number of entrants seeking to capture market share, intensifying competition across the board.

Companies like Bluebird Bio, Inc. and Spark Therapeutics, Inc. are at the forefront of developing groundbreaking gene therapies that target the root causes of SCID. Their commitment to innovation and patient-centric approaches has garnered significant interest from both investors and healthcare providers, solidifying their positions in the marketplace. Furthermore, companies such as Amgen Inc. and AbbVie Inc. leverage their expertise in immunology to create complementary therapies that address the unique challenges posed by SCID, further enhancing their competitive standing. As the market evolves, the competition is likely to intensify, compelling existing players to focus on continuous improvement and differentiation of their offerings to meet the diverse needs of SCID patients.

In addition to these well-established companies, emerging players such as Orgenesis Inc. and Regeneron Pharmaceuticals, Inc. are gaining traction by focusing on innovative treatment modalities and exploring niche markets within the SCID landscape. Their agility and adaptability allow them to pivot and respond to changing market dynamics effectively. As research continues to unveil new insights into the genetic underpinnings of SCID, these emerging players may play a crucial role in developing novel therapies that cater to the unmet needs of patients. The overall competitive landscape will depend on how well companies navigate the challenges posed by regulatory environments, technological advancements, and evolving patient demands, ultimately shaping the future of the SCID market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 AbbVie Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Novartis AG
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Sanofi S.A.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Orgenesis Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Merck & Co., Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Bluebird Bio, Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Genzyme Corporation
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 GlaxoSmithKline plc
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Gilead Sciences, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Spark Therapeutics, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 BioMarin Pharmaceutical Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Janssen Pharmaceuticals, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Regeneron Pharmaceuticals, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Takeda Pharmaceutical Company Limited
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Severe Combined Immunodeficiency Market, By Application
    • 6.1.1 Pediatrics
    • 6.1.2 Adults
  • 6.2 Severe Combined Immunodeficiency Market, By Product Type
    • 6.2.1 Gene Therapy
    • 6.2.2 Enzyme Replacement Therapy
    • 6.2.3 Stem Cell Transplantation
    • 6.2.4 Immunoglobulin Therapy
    • 6.2.5 Others
  • 6.3 Severe Combined Immunodeficiency Market, By Ingredient Type
    • 6.3.1 Adenosine Deaminase Deficiency
    • 6.3.2 IL-2 Receptor Gamma Chain Deficiency
    • 6.3.3 Janus Kinase 3 Deficiency
    • 6.3.4 RAG1 or RAG2 Deficiency
    • 6.3.5 Others
  • 6.4 Severe Combined Immunodeficiency Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Specialty Clinics
    • 6.4.3 Retail Pharmacies
    • 6.4.4 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Severe Combined Immunodeficiency Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Severe Combined Immunodeficiency market is categorized based on

By Product Type

• Gene Therapy
• Enzyme Replacement Therapy
• Stem Cell Transplantation
• Immunoglobulin Therapy
• Others

By Application

• Pediatrics
• Adults

By Distribution Channel

• Hospitals
• Specialty Clinics
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Adenosine Deaminase Deficiency
• IL-2 Receptor Gamma Chain Deficiency
• Janus Kinase 3 Deficiency
• RAG1 or RAG2 Deficiency
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Novartis AG
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Amgen Inc.
• Bluebird Bio, Inc.
• Sanofi S.A.
• AbbVie Inc.
• Orgenesis Inc.
• Spark Therapeutics, Inc.
• Janssen Pharmaceuticals, Inc.
• Regeneron Pharmaceuticals, Inc.
• Genzyme Corporation
• Takeda Pharmaceutical Company Limited
• Merck & Co., Inc.
• BioMarin Pharmaceutical Inc.